These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 24641952

  • 1. Characterization of [¹²⁵I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta.
    Kuc RE, Maguire JJ, Siew K, Patel S, Derksen DR, Margaret Jackson V, O'Shaughnessey KM, Davenport AP.
    Life Sci; 2014 May 02; 102(2):134-8. PubMed ID: 24641952
    [Abstract] [Full Text] [Related]

  • 2. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
    Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M.
    Circulation; 2008 May 06; 117(18):2340-50. PubMed ID: 18427132
    [Abstract] [Full Text] [Related]

  • 3. Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay.
    Chen J, Bai G, Yang Y, Geng P, Cao Y, Zhu Y.
    Peptides; 2007 Apr 06; 28(4):928-34. PubMed ID: 17267075
    [Abstract] [Full Text] [Related]

  • 4. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
    Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH, Drucker DJ, Husain M.
    Endocrinology; 2010 Apr 06; 151(4):1520-31. PubMed ID: 20172966
    [Abstract] [Full Text] [Related]

  • 5. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
    Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jetté L, Benquet C, Drucker DJ.
    Diabetes; 2003 Mar 06; 52(3):751-9. PubMed ID: 12606517
    [Abstract] [Full Text] [Related]

  • 6. Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts.
    Barakat GM, Nuwayri-Salti N, Kadi LN, Bitar KM, Al-Jaroudi WA, Bikhazi AB.
    Gen Physiol Biophys; 2011 Mar 06; 30(1):34-44. PubMed ID: 21460410
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.
    Regul Pept; 2012 Nov 10; 179(1-3):91-100. PubMed ID: 22989472
    [Abstract] [Full Text] [Related]

  • 8. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor.
    Roed SN, Wismann P, Underwood CR, Kulahin N, Iversen H, Cappelen KA, Schäffer L, Lehtonen J, Hecksher-Soerensen J, Secher A, Mathiesen JM, Bräuner-Osborne H, Whistler JL, Knudsen SM, Waldhoer M.
    Mol Cell Endocrinol; 2014 Feb 15; 382(2):938-49. PubMed ID: 24275181
    [Abstract] [Full Text] [Related]

  • 9. Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency.
    Sebokova E, Christ AD, Wang H, Sewing S, Dong JZ, Taylor J, Cawthorne MA, Culler MD.
    Endocrinology; 2010 Jun 15; 151(6):2474-82. PubMed ID: 20382695
    [Abstract] [Full Text] [Related]

  • 10. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.
    Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM.
    J Biol Chem; 2012 Feb 03; 287(6):3642-58. PubMed ID: 22147710
    [Abstract] [Full Text] [Related]

  • 11. A strategy for fusion expression and preparation of functional glucagon-like peptide-1 (GLP-1) analogue by introducing an enterokinase cleavage site.
    Liu Y, Ren L, Ge L, Cui Q, Cao X, Hou Y, Bai F, Bai G.
    Biotechnol Lett; 2014 Aug 03; 36(8):1675-80. PubMed ID: 24737080
    [Abstract] [Full Text] [Related]

  • 12. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.
    Runge S, Schimmer S, Oschmann J, Schiødt CB, Knudsen SM, Jeppesen CB, Madsen K, Lau J, Thøgersen H, Rudolph R.
    Biochemistry; 2007 May 15; 46(19):5830-40. PubMed ID: 17444618
    [Abstract] [Full Text] [Related]

  • 13. GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes.
    Tomas E, Stanojevic V, Habener JF.
    Horm Metab Res; 2010 Aug 15; 42(9):657-62. PubMed ID: 20645222
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis and in vitro characterization of Glucagon-Like Peptide-1 derivatives for pancreatic beta cell imaging by SPECT.
    Behnam Azad B, Rota VA, Breadner D, Dhanvantari S, Luyt LG.
    Bioorg Med Chem; 2010 Feb 15; 18(3):1265-72. PubMed ID: 20056547
    [Abstract] [Full Text] [Related]

  • 15. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor.
    Nuche-Berenguer B, Portal-Núñez S, Moreno P, González N, Acitores A, López-Herradón A, Esbrit P, Valverde I, Villanueva-Peñacarrillo ML.
    J Cell Physiol; 2010 Nov 15; 225(2):585-92. PubMed ID: 20506394
    [Abstract] [Full Text] [Related]

  • 16. The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice.
    Rolin B, Deacon CF, Carr RD, Ahrén B.
    Eur J Pharmacol; 2004 Jun 28; 494(2-3):283-8. PubMed ID: 15212985
    [Abstract] [Full Text] [Related]

  • 17. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
    Li C, Huan Y, Shen N, Ji L, Sun S, Liu S, Liu Q, Gao L, Tan F, Wang Y, Shen Z.
    Biochem Biophys Res Commun; 2010 Oct 01; 400(4):563-8. PubMed ID: 20804731
    [Abstract] [Full Text] [Related]

  • 18. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
    Miranda LP, Winters KA, Gegg CV, Patel A, Aral J, Long J, Zhang J, Diamond S, Guido M, Stanislaus S, Ma M, Li H, Rose MJ, Poppe L, Véniant MM.
    J Med Chem; 2008 May 08; 51(9):2758-65. PubMed ID: 18412318
    [Abstract] [Full Text] [Related]

  • 19. Constructing glucagon like peptide-1 receptor fused with derivatives of GFP for visualizing protein-protein interaction in living cells.
    Bavec A.
    Mol Biol Rep; 2010 Jul 08; 37(6):2749-55. PubMed ID: 19757164
    [Abstract] [Full Text] [Related]

  • 20. Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
    Li N, Lu J, Willars GB.
    PLoS One; 2012 Jul 08; 7(10):e47936. PubMed ID: 23094100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.